Renal cell carcinoma, the most common form of kidney cancer, has some particular metabolic quirks. The cancer accumulates large amounts of lipids inside its cells, giving it a characteristic “clear cell” appearance, almost like little bubbles of water under the microscope.
A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. High-grade neuroendocrine cancer is a complex and aggressive condition that has seen few medical advances, in part because its rarity has subdued research investment. Patients have few options beyond conventional chemotherapy.
New research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, scientists has found that targeting ZNF638, a “master regulator” protein that silences retroviruses, can induce an antiviral response in glioblastoma.
Immune checkpoint inhibitors have been a game-changer in oncology. Tumors often have proteins on them that tell your immune system not to attack. Checkpoint inhibitors — which work by blocking these proteins so your immune system continues to fight the tumor — have provided new options for many people with advanced or metastatic cancer who were left with limited options.
The Department of Radiation Oncology at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has become the first in North America to obtain the prestigious International Stereotactic Radiosurgery Society (ISRS) Certification for stereotactic radiosurgery (SRS) treatments of malignant and benign brain disorders.
When Karen Wilford first battled breast cancer in 2008, her doctors ordered chemotherapy, radiation and surgery. She remembers being told she’d lose her hair and was given a wig and makeup to help her feel better. Things were noticeably different when the cancer returned as stage 4 a few years ago.
Recent research has established a connection between a person’s “biological age” and their risk of developing colon polyps, which are known to be a risk factor for colorectal cancer. Biological age can be measured through various tests and reflects the impacts of lifestyle choices, genetics and environmental factors on an individual’s body. Unlike chronological age, which simply counts the years a person has lived, biological age is based on physiological markers.
Patients with multiple myeloma are living longer, healthier lives thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease, the second most common blood cancer. “We’d like to develop a curative treatment for multiple myeloma, and we are at the point where that’s possible,” said C. Ola Landgren, M.D., Ph.D., who leads the Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
There’s good news on the treatment horizon for two typically slow-growing versions of lymphoma: follicular lymphoma and marginal zone lymphoma. Research presented by physicians from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, at the American Society of Hematology’s 2024 meeting in San Diego describes positive results for the antibody drug loncastuximab tesirine (Zynlonta) in patients with high-risk forms of these two blood cancers.
Today, at age 31, Manuel Garcia has been cancer-free for five years. He works at his family’s business, representing manufacturers of high-end decorative plumbing. And he’s back in the sky, leaping out of airplanes again — and off cliffs and bridges, too.
